Cita APA

Weber, M. S., Prod’homme, T., Youssef, S., Dunn, S. E., Steinman, L., & Zamvil, S. S. (2014). Neither T-helper type 2 nor Foxp3(+) regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. BioMed Central.

Citación estilo Chicago

Weber, Martin S., Thomas Prod’homme, Sawsan Youssef, Shannon E. Dunn, Lawrence Steinman, y Scott S. Zamvil. Neither T-helper Type 2 nor Foxp3(+) Regulatory T Cells Are Necessary for Therapeutic Benefit of Atorvastatin in Treatment of Central Nervous System Autoimmunity. BioMed Central, 2014.

Cita MLA

Weber, Martin S., et al. Neither T-helper Type 2 nor Foxp3(+) Regulatory T Cells Are Necessary for Therapeutic Benefit of Atorvastatin in Treatment of Central Nervous System Autoimmunity. BioMed Central, 2014.